NGLFINE vs SENORES: Stock Comparison
NGL Fine-Chem Limited vs Senores Pharmaceuticals Limited
Live data: 22 July 2026, 3:04 PM IST • Source: NSE and company filings
Senores Pharmaceuticals Limited is the larger company by market capitalisation. NGL Fine-Chem Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Senores Pharmaceuticals Limited shows a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of NGL Fine-Chem Limited and Senores Pharmaceuticals Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | NGLFINE | SENORES |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | NGLFINE | SENORES |
|---|---|---|
| Live Price | ₹3,260 | ₹1,392 |
| Day Change | 0.7% | -0.85% |
| Volume | 5,595 | 3.39 L |
| 52-Week High | ₹3,329 | ₹1,509.8 |
| 52-Week Low | ₹1,175.5 | ₹601.1 |
| Distance from 52W High | -2.07% | -7.8% |
Valuation
| Metric | NGLFINE | SENORES |
|---|---|---|
| Market Cap | ₹2,008 Cr | ₹6,415 Cr |
| P/E Ratio | 41.23x | 53.33x |
| P/B Ratio | 6.03x | 6.94x |
| EPS | ₹78.04 | ₹26.36 |
| Book Value | ₹532.95 | ₹235.1 |
| Dividend Yield | 0.05% | 0% |
Growth
| Metric | NGLFINE | SENORES |
|---|---|---|
| Revenue Growth (TTM YoY) | 57.2% | 53.4% |
| EPS Growth (TTM YoY) | 1,539.8% | 108.9% |
| Qtr Sales Growth | 57.1% | 53.4% |
| Qtr Profit Growth | 2,398% | 77.3% |
Profitability & Leverage
| Metric | NGLFINE | SENORES |
|---|---|---|
| ROE | 15.7% | 13.4% |
| ROCE | 17% | 15.1% |
| Net Margin | 9.59% | 18.5% |
| Operating Margin | 14.5% | 26.6% |
| Debt to Equity | 0.33x | 0.37x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | NGLFINE | SENORES |
|---|---|---|
| Promoter Holding | 72.74% | 39.54%▲ 0.02 pp |
| FII Holding | 0.03%▲ 0.03 pp | 3.64%▲ 0.29 pp |
| DII Holding | 0% | 9.61%▲ 0.3 pp |
| Public Holding | 27.24%▼ 0.02 pp | 40.93%▼ 0.61 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NGL Fine-Chem Limited and Senores Pharmaceuticals Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.